13F filer · CIK 1674546
Bellevue Group AG
ZURICH, V8 · filing since Q1 2016 · last filing Aug 14, 2026
Reported value
$4.8B
+$550.7M vs prior
Positions
148
New / sold out
17 / 24
Added / reduced
41 / 66
Turnover
23.5%
buys $1.1B · sells $1.1B
Top-10 weight
42.9%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | AMGEN INC | +556,192 | +188.3% | +$201.4M |
| Added | INSMED INC | +1,383,384 | +13787.0% | +$147.5M |
| Added | GILEAD SCIENCES INC | +988,893 | +84.5% | +$124.9M |
| Added | ORUKA THERAPEUTICS INC | +1,150,182 | +226.9% | +$109.5M |
| Added | UNITED THERAPEUTICS CORP DEL | +186,438 | +8976.3% | +$101.0M |
| Added | BRIDGEBIO PHARMA INC | +1,164,129 | +4587.3% | +$86.7M |
| Added | VAXCYTE INC | +781,238 | +65.6% | +$45.4M |
| New | AVALYN PHARMACEUTICALS INC | +1,350,000 | – | +$44.4M |
| New | CG ONCOLOGY INC | +493,596 | – | +$35.1M |
| New | SEAPORT THERAPEUTICS INC | +1,100,000 | – | +$23.9M |
48 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | KRYSTAL BIOTECH INC | -404,255 | -83.9% | $-150.2M |
| Reduced | REVOLUTION MEDICINES INC | -496,442 | -32.1% | $-93.0M |
| Reduced | REGENERON PHARMACEUTICALS | -121,383 | -43.6% | $-75.7M |
| Reduced | ALNYLAM PHARMACEUTICALS INC | -233,451 | -99.5% | $-70.3M |
| Reduced | IONIS PHARMACEUTICALS INC | -846,407 | -46.5% | $-67.1M |
| Reduced | SCHOLAR ROCK HLDG CORP | -1,135,026 | -31.7% | $-62.4M |
| Reduced | TANGO THERAPEUTICS INC | -1,705,818 | -71.1% | $-53.3M |
| Reduced | VERTEX PHARMACEUTICALS INC | -103,274 | -15.1% | $-51.3M |
| Sold out | EDGEWISE THERAPEUTICS INC | -1,528,518 | -100.0% | $-48.1M |
| Reduced | ENLIVEN THERAPEUTICS INC | -830,867 | -35.8% | $-42.2M |
80 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | AMGEN INCCOM | 851,550 | $308.4M | 6.49% |
| 2 | VERTEX PHARMACEUTICALS INCCOM | 578,634 | $287.4M | 6.05% |
| 3 | ARGENX SESPONSORED ADR | 301,000 | $279.3M | 5.88% |
| 4 | GILEAD SCIENCES INCCOM | 2,158,772 | $272.7M | 5.74% |
| 5 | REVOLUTION MEDICINES INCCOM | 1,048,014 | $196.3M | 4.13% |
| 6 | ORUKA THERAPEUTICS INCCOM | 1,657,190 | $157.7M | 3.32% |
| 7 | INSMED INCCOM PAR $.01 | 1,393,418 | $148.6M | 3.13% |
| 8 | SCHOLAR ROCK HLDG CORPCOM | 2,449,547 | $134.7M | 2.83% |
| 9 | NUVALENT INCCOM | 1,053,268 | $130.1M | 2.74% |
| 10 | VIRIDIAN THERAPEUTICS INCCOM | 6,731,909 | $123.7M | 2.60% |
138 more rows. Subscribe for $29/month to see every row, download the data and use the API.